PubRank

Bart Keymeulen

Author PubWeight™ 32.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A 2005 2.70
2 Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006 2.64
3 Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010 1.91
4 Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008 1.67
5 Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009 1.27
6 The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation. Diabetes Care 2002 1.16
7 Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 2011 1.12
8 The ankle--brachial index and the diabetic foot: a troublesome marriage. Ann Vasc Surg 2011 1.07
9 Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun 2011 1.00
10 Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010 0.96
11 A view on beta cell transplantation in diabetes. Ann N Y Acad Sci 2002 0.94
12 Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. J Vasc Interv Radiol 2005 0.93
13 Predictors of progression to Type 1 diabetes: preparing for immune interventions in the preclinical disease phase. Expert Rev Clin Immunol 2013 0.91
14 Comparative evaluation of simple indices of graft function after islet transplantation. Transplantation 2011 0.88
15 Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005 0.88
16 Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transpl Int 2003 0.86
17 Potential of protein phosphatase inhibitor 1 as biomarker of pancreatic β-cell injury in vitro and in vivo. Diabetes 2013 0.85
18 Primary closure with a filleted hallux flap after transmetatarsal amputation of the big toe for osteomyelitis in the diabetic foot: a short series of four cases. Int J Low Extrem Wounds 2012 0.83
19 Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation 2009 0.83
20 Beta-cell transplantation restores metabolic control and quality of life in a patient with subcutaneous insulin resistance. Diabetes Care 2004 0.80
21 Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. Transplantation 2008 0.80
22 Screening for silent myocardial ischaemia in patients with type 2 diabetes mellitus: a quest to improve selection of the target screening population. Acta Cardiol 2011 0.80
23 Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. J Clin Endocrinol Metab 2002 0.80
24 Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009 0.79
25 Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. Transplantation 2013 0.78
26 Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients. J Clin Endocrinol Metab 2014 0.78
27 Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care 2009 0.78
28 Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipients. Diabetes Care 2013 0.76
29 A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R D 2006 0.76
30 Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes Metab Res Rev 2011 0.75
31 Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. Transplantation 2014 0.75
32 Age and early graft function relate with risk-benefit ratio of allogenic islet transplantation under Anti-thymocyte globulin - Mycophenolate mofetil - Tacrolimus immune suppression. Transplantation 2016 0.75
33 Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. PLoS One 2017 0.75
34 Identification of donor origin and condition of transplanted islets in situ in the liver of a type 1 diabetic recipient. Cell Transplant 2016 0.75